MDGL250516C460000
- 2.41
- 0.000.00%
Madrigal Pharmaceuticals Newsroom
Madrigal Pharmaceuticals Price Target Raised to $460.00/Share From $422.00 by B. Riley Securities
Madrigal Pharmaceuticals Is Maintained at Buy by Canaccord Genuity
Madrigal Pharmaceuticals Analyst Ratings
UBS Adjusts Madrigal Pharmaceuticals Price Target to $458 From $441, Maintains Buy Rating
Analysts Conflicted on These Healthcare Names: Madrigal Pharmaceuticals (MDGL) and AptarGroup (ATR)
BofA Securities Maintains Madrigal Pharmaceuticals(MDGL.US) With Sell Rating, Raises Target Price to $248
JMP Securities Maintains Madrigal Pharmaceuticals(MDGL.US) With Buy Rating, Raises Target Price to $470
TD Cowen Maintains Madrigal Pharmaceuticals(MDGL.US) With Buy Rating, Maintains Target Price $390
Madrigal Pharmaceuticals: Strong Financial Performance and Strategic Positioning Justify Buy Rating
JMP Securities Reaffirms Their Buy Rating on Madrigal Pharmaceuticals (MDGL)
Earnings Call Summary | Madrigal Pharmaceuticals(MDGL.US) Q1 2025 Earnings Conference
Madrigal Pharmaceuticals Advances Rezdiffra Market Penetration With 33% Quarterly Sales Growth
Madrigal Pharmaceuticals Q1 Loss Narrows
Madrigal Pharmaceuticals | 10-Q: Q1 2025 Earnings Report
Madrigal Pharmaceuticals GAAP EPS of -$3.32 Beats by $0.41, Revenue of $137.3M Beats by $23.11M
Earnings Flash (MDGL) Madrigal Pharmaceuticals Posts Q1 Loss $-3.32 Per Share, Vs. FactSet Est of $-3.94
Madrigal Pharmaceuticals | 8-K: Madrigal Pharmaceuticals Reports First-Quarter 2025 Financial Results and Provides Corporate Updates
Madrigal Pharmaceuticals 1Q Research and Development Expense $44.2M >MDGL
Express News | Madrigal Pharmaceuticals Q1 Net Income USD -73.238 Million
Press Release: Madrigal Pharmaceuticals Reports First-Quarter 2025 Financial Results and Provides Corporate Updates